|
Featured Report:
Pharmaceutical Company Outlook to 2013
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Corporate & Fiscal > Wyeth:
Pipeline - Products - Performance - Potential
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Wyeth is one of the world’s largest research-based pharmaceutical and healthcare products companies and is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, biotechnology products, vaccines, non-prescription medicines and animal health products. Wyeth currently operates in over 145 countries worldwide.
Fiscal 2007 was a strong year for Wyeth, with the company achieving record levels of sales and income. In terms of pharmaceuticals sales, Wyeth maintained its place in the top ten research-based pharmaceutical companies worldwide. This success was based on strong growth of its biotechnology products Enbrel and Prevnar, the launch of Torisel and Lybrel, and the company's continued expansion into China, the Middle East and Latin America. Furthermore, Wyeth reported successful cost-management efforts through the efficient implementation of its "Project Springboard" scheme.
Wyeth’s growth is based on a strong foundation of products, which includes Effexor, Protonix, Enbrel, Prevnar, Zosyn, and the Premarin franchise. Productivity, coupled with significant investment in facilities (for example, Wyeth’s US$2 billion biotech manufacturing site in Grange Castle, Ireland) allowed the company to achieve record levels of production for its lead vaccine, Prevnar, and accommodation of the increasing demand for Enbrel, which is fast becoming one of the world’s leading rheumatoid arthritis treatments.
However, sustained growth is threatened by the loss of patent protection for several products including Effexor (Wyeth’s top-seller), Prevnar and Zosyn. Wyeth has assembled a strong pipeline, which may yield compounds to follow in the footsteps of these leading products. Desvenlafaxine and the 13-valent pneumococcal vaccine have the potential to succeed Effexor and Prevnar respectively, whilst the recently-launched Tygacil is anticipated to provide a boost to the Anti-infective therapeutic area, whose sales were set to suffer with the loss of Zosyn’s market protection.
Top of Page
Table of Contents
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
Key product analysis and forecasting
Neuroscience
Effexor (venlafaxine)
Pristiq (desvenlafaxine succinate)
Gastroenterology
Protonix (pantoprazole)
Relistor (methylnaltrexone)
Vaccines
Prevnar/Prevenar (7-valent glycoconjugate)
Musculoskeletal
Enbrel (etanercept)
rhBMP-2/Inductos (dibotermin alpha)
Women's Healthcare/Contraception
Lybrel/Anya (levonorgestral+ethinyloestradiol)
Oral contraceptives
Premarin (conjugated oestrogens)
Anti-Infectives
Tazocin/Zosyn (tazobactam)
Tygacil (tigecycline)
Haemophilia
BeneFIX (recombinant Factor IX)
ReFacto (recombinant Factor VIII)
Immunology
Rapamune (sirolimus)
Oncology
Torisel (temsirolimus)
OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|
